Adalvo is pleased to announce the addition of Edoxaban film coated tablets to our product Portfolio. Dossier readiness for Edoxaban is expected in Q1 2024.
Our product is being developed in collaboration with one of our strategic partners, based on the reference brand Lixiana.
Lixiana is indicated in prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) & also in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and for the prevention of recurrent DVT and PE in adults
Our product offers the unique combination of an easy-to-use oral anticoagulant with proven efficacy across a broad range of patients and a better bleeding profile compared to well-managed warfarin.
The brand sold approximately $1.9Bn globally in 2021, having a significant growth potential with Global 3Y CAGR at 19%, according to IQVIA.
With our clearly defined product pathway, we believe Adalvo will be amongst the first wave of filers, and we expect to achieve day-1 launch in all major markets.
Adalvo is working on several interesting Cardiovascular projects, as depicted below. This highlights our ability to offer differentiated, value-added products to our partners.
Disclaimer: Products which are subject to patent protection are currently not offered or made available in countries where patents are in force